Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Gerstner

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade GliomaEudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Brain : a Journal of Neurology|September 21, 2022
Regional healthy brain activity, glioma occurrence and symptomatologyTianne Numan, Lucas C Breedt, Bernardo de A P C Maciel, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
NPJ Precision Oncology|June 7, 2018
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimensPriscilla K Brastianos, Naema Nayyar, Daniel Rosebrock, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade GliomaEudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Brain : a Journal of Neurology|September 21, 2022
Regional healthy brain activity, glioma occurrence and symptomatologyTianne Numan, Lucas C Breedt, Bernardo de A P C Maciel, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
NPJ Precision Oncology|June 7, 2018
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimensPriscilla K Brastianos, Naema Nayyar, Daniel Rosebrock, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Pageof 14